Literature DB >> 27900851

Metastatic pathways in patients with cutaneous melanoma.

Nikki R Adler1,2, Andrew Haydon1,3, Catriona A McLean4, John W Kelly1, Victoria J Mar1,2,5.   

Abstract

Metastasis represents the end product of an elaborate biological process, which is determined by a complex interplay between metastatic tumour cells, host factors and homoeostatic mechanisms. Cutaneous melanoma can metastasize haematogenously or lymphogenously. The three predominant models that endeavour to explain the patterns of melanoma progression are the stepwise spread model, the simultaneous spread model and the model of differential spread. The time course to the development of metastases differs between the different metastatic routes. There are several clinical and histopathological risk factors for the different metastatic pathways. In particular, patient sex and the anatomical location of the primary tumour influence patterns of disease progression. There is limited existing evidence regarding the relationship between tumour mutation status, other diagnostic and prognostic biomarkers and the metastatic pathways of primary cutaneous melanoma. This knowledge gap needs to be addressed to better identify patients at high risk of disease recurrence and personalize surveillance strategies.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biomarker; cutaneous melanoma; metastasis; metastatic pathways

Mesh:

Year:  2016        PMID: 27900851     DOI: 10.1111/pcmr.12544

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  14 in total

1.  Sentinel bruising as a presentation of metastatic melanoma.

Authors:  Lloyd Steele; Chit Cheng Yeoh
Journal:  BMJ Case Rep       Date:  2019-02-25

2.  Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.

Authors:  Laura Calomarde-Rees; Rosario García-Calatayud; Celia Requena Caballero; Esperanza Manrique-Silva; Víctor Traves; Zaida García-Casado; Virtudes Soriano; Rajiv Kumar; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

Review 3.  Review of diagnostic, prognostic, and predictive biomarkers in melanoma.

Authors:  Jacob S Ankeny; Brian Labadie; Jason Luke; Eddy Hsueh; Jane Messina; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

Review 4.  MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.

Authors:  Anita Thyagarajan; Ahmed Shaban; Ravi Prakash Sahu
Journal:  J Pharmacol Exp Ther       Date:  2017-10-20       Impact factor: 4.030

5.  Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation.

Authors:  Noelia A Massari; Melisa B Nicoud; Lorena Sambuco; Graciela P Cricco; Diego J Martinel Lamas; María V Herrero Ducloux; Horacio Blanco; Elena S Rivera; Vanina A Medina
Journal:  Oncotarget       Date:  2017-04-18

6.  Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma.

Authors:  Ana Carolina Monteiro; Julienne K Muenzner; Fernando Andrade; Flávia Eichemberger Rius; Christian Ostalecki; Carol I Geppert; Abbas Agaimy; Arndt Hartmann; André Fujita; Regine Schneider-Stock; Miriam Galvonas Jasiulionis
Journal:  Mol Oncol       Date:  2019-05-25       Impact factor: 6.603

7.  BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas.

Authors:  Atte A Manninen; Maria Gardberg; Susanna Juteau; Suvi Ilmonen; Joonas Jukonen; Noora Andersson; Olli Carpén
Journal:  PLoS One       Date:  2019-04-30       Impact factor: 3.240

8.  Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts.

Authors:  Ruixia Huang; Lise Mari K Andersen; Einar K Rofstad
Journal:  J Transl Med       Date:  2017-10-10       Impact factor: 5.531

9.  Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis.

Authors:  Ping Zhou; Jiaqi Qin; Yuan Li; Guoxia Li; Yinsong Wang; Ning Zhang; Peng Chen; Chunyu Li
Journal:  J Exp Clin Cancer Res       Date:  2017-09-02

10.  PAX3d mRNA over 2.76 copies/µL in the bloodstream predicts cutaneous malignant melanoma relapse.

Authors:  Chiara Autilio; Carmela Paolillo; Maria Michela Lavieri; Krizia Pocino; Elisa De Paolis; Enrico Di Stasio; Paolo Marchetti; Cappellini Antonini Gian Carlo; Ettore Capoluongo
Journal:  Oncotarget       Date:  2017-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.